Fucosylated glycoproteins as markers of liver disease

Disease Markers

Volumn 25, Issue 4-5, 2008, Pages 259-265

  Mehta, Anand ^a   Block, Timothy M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Fucosylation; Hepatitis B virus; Hepatitis C virus; Liver cancer; Liver fibrosis

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLYCOPROTEIN; IMMUNOGLOBULIN G; ONCOFETAL ANTIGEN;

CELL POLARITY; FUCOSYLATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; REVIEW;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 58149400525     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/264594     Document Type: Review

References (52)

1. A. Lok and B. McMahon, Chronic hepatitis B, Hepatology 34(6) (2001), 1225-1241.
2. A.S. Lok, Natural history and control of perinatally acquired hepatitis B virus infection, Dig Dis 10(1) (1992), 46-52.
3. J.A. Marrero, Hepatocellular carcinoma, Curr Opin Gastroenterol 22(3) (2006), 248-253.
4. M. Sherman, Hepatocellular carcinoma: epidemiology, risk factors, and screening, Semin Liver Dis 25(2) (2005), 143-154.
5. B.S. Anand, Cirrhosis of liver, West J Med 171(2) (1999), 110-115.
6. T.M. Block, A.S. Mehta, C.J. Fimmel and R. Jordan, Molecular viral oncology of hepatocellular carcinoma, Oncogene 22(33) (2003), 5093-5107.
7. A.M. Di Bisceglie, R.L. Carithers, Jr. and G.J. Gores, Hepatocellular carcinoma, Hepatology 28(4) (1998), 1161-1165.
8. S.L. Fung and A.S. Lok, Management of hepatitis B patients with antiviral resistance, Antivir Ther 9(6) (2004), 1013-1026.
9. Y.O. Kweon, Z.D. Goodman, J.L. Dienstag, E.R. Schiff, N.A. Brown, E. Burchardt, R. Schoonhoven, D.A. Brenner and M.W. Fried, Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B, J Hepatol 35(6) (2001), 749-755.
10. Y.F. Liaw, Results of lamivudine trials in Asia, J Hepatol 39(Suppl 1) (2003), S111-115.
11. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, F. Gudat, H. Denk, V. Desmet, G. Korb, R.N. MacSween et al., Histological grading and staging of chronic hepatitis, J Hepatol 22(6) (1995), 696-699.
12. R.G. Knodell, K.G. Ishak, W.C. Black, T.S. Chen, R. Craig, N. Kaplowitz, T.W. Kiernan and J. Wollman, Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis, Hepatology 1(5) (1981), 431-435.
13. R.J. Fontana and A.S. Lok, Noninvasive monitoring of patients with chronic hepatitis C, Hepatology 36(5 Suppl 1) (2002), S57-64.
14. M.E. Alpert, J. Uriel and B. de Nechaud, alpha fetogloblin in the diagnosis of human hepatoma, N Engl J Med 278 (1968), 984-986.
15. E. Ruoslahti, M. Salaspuro, H. Pihko, L. Andersson and M. Seppala, Serum alpha-fetoprotein: diagnostic significance in liver disease, Br Med J 2(918) (1974), 527-529.
16. A.M.a.J.H.H. Di Bisceglie, Elevations in serum alphafetoprotein levels in patients with chronic hepatitis B, Cancer 64(10) (1989), 2117-2120.
17. H. Nakabayashi, K. Watanabe, A. Saito, A. Otsuru, K. Sawadaishi and T. Tamaoki, Transcriptional regulation of alpha-fetoprotein expression by dexamethasone in human hepatoma cells, J Biol Chem 264(1) (1989), 266-271.
18. K. Sawadaishi, T. Morinaga and T. Tamaoki, Interaction of a hepatoma-specific nuclear factor with transcription-regulatory sequences of the human alpha-fetoprotein and albumin genes, Mol Cell Biol 8(12) (1988), 5179-5187.
19. J. Breborowicz, A. Mackiewicz and D. Breborowicz, Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis, Scand J Immunol 14(1) (1981), 15-20.
20. J. Miyazaki, Y. Endo and T. Oda, Lectin affinities of alpha-fetoprotein in liver cirrhosis, hepatocellular carcinoma and metastatic liver tumor, Acta Hepatol Jpn 22 (1981), 1559-1568.
21. P.J. Johnson, T.C. Poon, N.M. Hjelm, C.S. Ho, C. Blake and S.K. Ho, Structures of disease-specific serum alpha-fetoprotein isoforms, Br J Cancer 83(10) (2000), 1330-1337.
22. K. Taketa, E. Ichikawa, H. Taga and H. Hirai, Antibody-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin affinity electrophoresis in agarose gels, Electrophoresis 6 (1985), 492-497.
23. K. Taketa, C. Sekiya, M. Namiki, K. Akamatsu, Y. Ohta, Y. Endo and K. Kosaka, Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions, Gastroenterology 99(2) (1990), 508-518.
24. K. Shiraki, K. Takase, Y. Tameda, M. Hamada, Y. Kosaka and T. Nakano, Aclinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients, Hepatology 22(3) (1995), 802-807.
25. W. Morelle, C. Flahaut, J.C. Michalski, A. Louvet, P. Mathurin and A. Klein, Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis, Glycobiology 16(4) (2006), 281-293.
26. K. Noda, E. Miyoshi, N. Uozumi, C.X. Gao, K. Suzuki, N. Hayashi, M. Hori and N. Taniguchi, High expression of alpha-1-6 fucosyltransferase during rat hepatocarcinogenesis, Int J Cancer 75(3) (1998), 444-450.
27. W.L. Hutchinson, M.Q. Du, P.J. Johnson and R. Williams, Fucosyltransferases: differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis, Hepatology 13(4) (1991), 683-688.
28. E. Miyoshi, K. Noda, Y. Yamaguchi, S. Inoue, Y. Ikeda, W. Wang, J.H. Ko, N. Uozumi, W. Li and N. Taniguchi, The alpha1-6-fucosyltransferase gene and its biological significance, Biochem Biophys Acta 1473(1) (1999), 9-20.
29. M.A. Comunale, M. Lowman, R.E. Long, J. Krakover, R. Philip, S. Seeholzer, A.A. Evans, H.W.L. Hann, T.M. Block and A.S. Mehta, Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma, Journal of Proteome Research 6(5) (2006), 308-315.
30. K. Yamashita, N. Koide, T. Endo, Y. Iwaki and A. Kobata, Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma, J Biol Chem 264(5) (1989), 2415-2423.
31. A. Naitoh, Y. Aoyagi and H. Asakura, Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma, J Gastroenterol Hepatol 14(5) (1999), 436-445.
32. N. Callewaert, H. Van Vlierberghe, A. Van Hecke, W. Laroy, J. Delanghe and R. Contreras, Noninvasive diagnosis of liver cirrhosis using DNA sequencer based total serum protein glycomics, Nature Medicine 10(4) (2004), 429-434.
33. T.M. Block, M.A. Comunale, M. Lowman, L.F. Steel, F.R. Romano, C. Fimmel, B.C. Tennant, W.T. London, A.A. Evans, B.S. Blumberg, R.A. Dwek, T.S. Mattu and A.S. Mehta, Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans, Proc Natl Acad Sci USA 102(3) (2005), 779-784.
34. R.R. Drake, E.E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta and O.J. Semmes, Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers, Mol Cell Proteomics 5(10) (2006), 1957-1967.
35. T. Nakagawa, N. Uozumi, M. Nakano, Y. Mizuno-Horikawa, N. Okuyama, T. Taguchi, J. Gu, A. Kondo, N. Taniguchi and E. Miyoshi, Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts, J Biol Chem 281(40) (2006), 29797-29806.
36. K. Moriwaki, K. Noda, T. Nakagawa, M. Asahi, H. Yoshihara, N. Taniguchi, N. Hayashi and E. Miyoshi, A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation, Glycobiology 17(12) (2007), 1311-1320.
37. A.S. Mehta, R.E. Long, M.A. Comunale, M. Wang, L. Rodemich, J. Krakover, R. Philip, J.A. Marrero, R.A. Dwek and T.M. Block, Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis, J Virol 82(3) (2008), 1259-1270.
38. U. Galili, E.A. Rachmilewitz, A. Peleg and I. Flechner, A unique natural human IgG antibody with anti-alpha-galactosyl specificity, J Exp Med 160(5) (1984), 1519-1531.
39. U. Galili, Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody, Springer Semin Immunopathol 15(2-3) (1993), 155-171.
40. U. Galili, F. Anaraki, A. Thall, C. Hill-Black and M. Radic, One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody, Blood 82(8) (1993), 2485-2493.
41. G.C. Lastra, S.J. Thompson, A.S. Lemonidis and C.J. Elson, Changes in the galactose content of IgG during humoral immune responses, Autoimmunity 28(1) (1998), 25-30.
42. Y. Kaneko, F. Nimmerjahn and J.V. Ravetch, Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation, Science 313(5787) (2006), 670-673.
43. J. Ewaschuk, R. Endersby, D. Thiel, H. Diaz, J. Backer, M. Ma, T. Churchill and K. Madsen, Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis, Hepatology 46(3) (2007), 841-850.
44. S.L. Friedman, A deer in the headlights: BAMBI meets liver fibrosis, Nat Med 13(11) (2007), 1281-1282.
45. E. Seki, S. De Minicis, C.H. Osterreicher, J. Kluwe, Y. Osawa, D.A. Brenner and R.F. Schwabe, TLR4 enhances TGF-beta signaling and hepatic fibrosis, Nat Med 13(11) (2007), 1324-1332.
46. S. Kellokumpu, R. Sormunen and I. Kellokumpu, Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH, FEBS Lett 516(1-3) (2002), 217-224.
47. R. Peracaula, G. Tabares, L. Royle, D.J. Harvey, R.A. Dwek, P.M. Rudd and R. de Llorens, Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins, Glycobiology 13(6) (2003), 457-470.
48. J. Taylor-Papadimitriou, J. Burchell, D.W. Miles and M. Dalziel, MUC1 and cancer, Biochim Biophys Acta 1455(2-3) (1999), 301-313.
49. Y.J. Kim and A. Varki, Perspectives on the significance of altered glycosylation of glycoproteins in cancer, Glycoconj J 14(5) (1997), 569-576.
50. J.W. Dennis, M. Granovsky and C.E. Warren, Glycoprotein glycosylation and cancer progression, Biochem Biophys Acta 1473(1) (1999), 21-34.
51. P.C. Kelleher, C.J. Walters, B.D. Myhre, B.C. Tennant, J.L. Gerin and P.J. Cote, Altered glycosylation of alpha-fetoprotein in hepadnavirus-induced hepatocellular carcinoma of the woodchuck, Cancer Lett 63(2) (1992), 93-99.
52. A.B. Ajdukiewicz, P.C. Kelleher, E.L. Krawitt, C.J. Walters, P.B. Mason, R.S. Koff and L. Belanger, Alpha-fetoprotein glycosylation is abnormal in some hepatocellular carcinoma, including white patients with a normal alpha-fetoprotein concentration, Cancer Lett 74(1-2) (1993), 43-50.